BioCentury on BioBusiness,
Politics and Policy
MPs extend British Biotech inquiry
Monday, July 20, 1998
LONDON - Members of the U.K. House of Commons Select Committee on
Science & Technology are to give up some of their summer holidays to continue their
investigation into the Millargate affair. Peter Lewis, the former research director at
British Biotech plc (LSE:BBG; BBIOY) has been asked to testify at hearings planned next
The decision to extend the hearings - the committee had originally
penciled in time for two meetings - was taken after last week's testimony from Goldman
Sachs analyst Jane Henderson, representatives of Perpetual plc and representatives of
Dresdner Kleinwort Benson. Committee member Ian Gibson told BioCentury that he and his
colleagues would continue the inquiry because the evidence that they have been given
"does not quite all add up."
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]